Immunitybio (IBRX) Stock
Clinical biotech developing cancer and infectious disease therapies. Here's the price, business snapshot, and what's worth knowing about Immunitybio in October 2026.
ImmunityBio Inc. (IBRX) is a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases. It pursues a pipeline of biologics, engineered cell approaches and vaccine candidates intended to stimulate or modulate the immune system, using viral-vector and cytokine-based platforms. With a market capitalisation of about $2.40 billion, the stock reflects investor expectations about its clinical programmes and potential commercial opportunities. Key value drivers include trial read-outs, regulatory decisions, partnerships and financing. Like most clinical-stage biotechs, it carries higher volatility and binary outcomes — successful trials can materially increase value, while setbacks can lead to sharp declines. Investors should monitor cash runway, R&D spending and pipeline progress. This summary is educational and not personal financial advice; suitability depends on your circumstances and you should consult a qualified financial adviser before acting.
Immunitybio (IBRX) Stock Forecast
Analyst price target, next 12 months
$10.29
+0.0% vs today's $10.29
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Immunitybio have a consensus 12-month target of $10.29, in line with the current price of $10.29.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying ImmunityBio's stock, anticipating it will reach a target price of $10.29.
Financial Health
ImmunityBio is performing well with strong revenue and nearly perfect profit margins, indicating solid business health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical read-outs and regulatory milestones can move the share price significantly, though outcomes are binary and uncertain.
Platform Technology
Viral-vector and cytokine-based approaches aim to enhance immune response; technological promise requires clinical validation.
Funding & Partnerships
Collaborations and capital raises affect runway and commercial prospects, but financing can dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
